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Background: Comparative genetic and biological studies on malignant tumor counterparts in human beings and
laboratory mice may be powerful gene discovery tools for blood cancers, including neoplasms of mature B-lymphocytes
and plasma cells such as Burkitt lymphoma (BL) and multiple myeloma (MM).
Methods: We used EMSA to detect constitutive NF-κB/STAT3 activity in BL- and MM-like neoplasms that spontaneously
developed in single-transgenic IL6 (interleukin-6) or MYC (c-Myc) mice, or in double-transgenic IL6MYC mice. qPCR
measurements and analysis of clinical BL and MM datasets were employed to validate candidate NF-κB/STAT3 target
genes.
Results: qPCR demonstrated that IL6- and/or MYC-dependent neoplasms in mice invariably contain elevated mRNA
levels of the NF-κB target genes, Cdkn1a and Fancd2. Clinical studies on human CDKN1A, which encodes the cell cycle
inhibitor and tumor suppressor p21, revealed that high p21 message predicts poor therapy response and survival in BL
patients. Similarly, up-regulation of FANCD2, which encodes a key member of the Fanconi anemia and breast cancer
pathway of DNA repair, was associated with poor outcome of patients with MM, particularly those with high-risk disease.
Conclusions: Our findings suggest that CDKN1A and FANCD2 are potential oncotargets in BL and MM, respectively.
Additionally, the IL-6- and/or MYC-driven mouse models of human BL and MM used in this study may lend themselves
to the biological validation of CDKN1A and FANCD2 as molecular targets for new approaches to cancer therapy and
prevention.
Keywords: p21 tumor suppressor, Fanconi anemia and breast cancer DNA damage repair, Genetically engineered
mouse models of human cancer, Molecularly targeted cancer therapyBackground
Comparative histopathologic, genomic and biological ana-
lyses of malignant tumor counterparts in humans and mice
afford a powerful approach to improve our understanding
of evolutionarily conserved signaling networks that underlie
oncogenesis and are thus of great significance for public
health. An important objective of cross-species analysis of
neoplastic development is the discovery of concordantly
deregulated genes that play an important role in tumor
development and progression, response to therapy, acquisi-
tion of drug resistance, and clinical outcome. Protein-
encoding genes that are overexpressed in cancer cells and* Correspondence: siegfried-janz@uiowa.edu
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unless otherwise stated.potentially inhibitable by small compounds are of particular
interest to that end, because they are actionable in terms of
molecularly targeted drug development. Here, we take ad-
vantage of MYC- [1], IL6- [2] and IL6MYC-transgenic (Tg)
mice [3,4] that recapitulate important features of human
Burkitt lymphoma (BL) or multiple myeloma (MM) to un-
cover up-regulated candidate cancer genes that might have
been overlooked in other studies. We show that MYC and/
or IL-6-driven B cell and plasma cell tumors of mice exhibit
constitutive NF-κB activity that leads to overexpression of
NF-κB target genes such as Cdkn1a and Fancd2. These
genes encode the well-established tumor suppressor, p21,
and a key member of the Fanconi anemia/breast cancer
DNA damage repair pathway, respectively. Interrogation of
a well-annotated clinical dataset (n = 351) suggested that
FANCD2 is a MM gene. Likewise, in vitro studies on tumoris is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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CDKN1A may be a BL oncogene. Although additional
work is warranted before the utility of CDKN1A and
FANCD2 as molecular targets for drug development can
be fully evaluated, our study underlines the value of com-
parative oncogenomic and molecular genetic research on
human-mouse cancer counterparts for developing new
approaches to cancer therapy and prevention.Results
Constitutive NF-κB and STAT3 activity in IL-6 and/or
MYC-driven B cell and plasma cell tumors in mice
Because NF-κB and STAT3 are important regulators of
B-lineage neoplasms in humans and mice, we used
EMSA to examine NF-κB and STAT3 activity in MACS-
purified B220+ samples from 19 primary tumors obtained
from single-transgenic IL-6 (n = 6) or MYC (n = 5) mice and
double-transgenic IL6MYC (n = 8) mice (Figure 1). Com-
pared to normal B220+ splenocytes used as control, all
tumor samples contained a significantly elevated DNA-
binding activity of both transcription factors (Figure 2A and
B). To ascertain the subunit composition of NF-κB dimers,
we performed super-shift assays using nuclear extracts
(NEs) from tumor cells isolated from enlarged spleens of
IL6MYC mice. We included antibodies (Abs) to all 5 NF-κB
subunits (Figure 2C) and observed notable shifts for three:
p50 (lane 2), p65 (lane 3) and c-Rel (lane 4). Ab to RelB
caused only a faint shift (lane 6) and p52 seemed to be unin-
volved (lane 5). Similar to our previous findings on the
MYC-dependent mouse lymphoma cell line iMycEμ [5], Ab
to p50 shifted two NF-κB-specific bands to higher
molecular-weight positions on EMSA gels, whereas Ab
to p65 or c-Rel shifted only the upper or lower band, re-
spectively. Both activated STAT3, pSTA3, and acetyl-
transferase p300, a positive regulator of NF-κB/STAT3
signaling [6,7], were physically associated with NF-κB in
IL6MYC tumor cells (lanes 7 and 8). Next, we con-
firmed these findings with the assistance of STAT3
super-shift assays, using the same NEs as in panel C
(Figure 2D). We found that three NF-κB subunits (p50,
lane 2; p65, lane 3; c-Rel, lane 4), pStat3 (lane 7) and
p300 (lane 8) participated in protein complexes that
were able to bind a canonical STAT3 DNA recognition
sequence. The results presented in Figure 2 suggested
that the constitutive NF-κB activity in IL6MYC tumors
is comprised of both p50 homo and p50 hetero (with
p65 and c-Rel) dimers that are further associated with
p300 and pSTAT3. While the association with the
former has not yet been reported to the best of our
knowledge, the latter finding is in agreement with re-
ports on the physical association of STAT3 and NF-κB
in various cell types [8] including MYC-transgenic B-
lymphocytes [5].Up-regulation of Cdkn1a and Fancd2 in mouse tumor
cells
qPCR analysis of RNA from tumor cells isolated from
seven different IL-6- and/or MYC-induced neoplasms
included in Figure 2A and B demonstrated that three
well-established NF-κB target genes were consistently
up-regulated in this sample: Cdkn1a, a target of the
tumor-suppressor p53, and two DNA repair genes,
Fancd2 and Xcrcc6 (Figure 3A). Mean Cdkn1a message
in tumor cells was 11.1-fold elevated compared to nor-
mal B cells (standard deviation 8.69; p = 0.0169 by
Mann–Whitney), whereas expression of Trp53 (encodes
p53) was down regulated (0.614 ± 0.219; p = 0.0006).
Fancd2 and Xcrcc6 expression was increased by a factor
of 4.27 ± 2.08 (p = 0.0006) and 1.97 ± 1.20 (p = 0.0169),
respectively. Median expression values of the 4 genes
varied significantly using Kruskall-Wallis test (p =
0.0006). Because the small amounts of tumor RNA avail-
able were insufficient to evaluate additional genes of
interest, we prepared RNA from another tumor set (n =
21) obtained from an independent cohort of IL6MYC
mice. Continuing with the qPCR analysis, we first con-
firmed the changes presented in Figure 3A (results not
shown) and then showed that the genes encoding aurora
kinase A (Aurka) and the germinal center B cell master
transcription factor Blimp-1 (Prdm1) were up-regulated
in tumor cells, whereas expression of Irf1 (interferon
regulatory factor 1, Egr1 (early growth response 1) and
Bcl2 (B cell leukemia 2) was decreased (Figure 3B). The
differences in gene expression were highly significant for
each gene individually (compared to normal B cells; p <
0.0001, Mann Whitney) and considered as a set (p <
0.0001, Kruskall-Wallis). Cdkn1a, Fancd2, Xcrcc6, Aurka
and Prdm1 are drug-inhibitable overexpressed protein-
encoding genes that might be of interest for the develop-
ment of molecularly targeted interventions.
CDKN1A is a candidate oncogene in human Burkitt
lymphoma (BL)
Cdkn1a was of special interest to us because (1) evi-
dence has emerged that p21 may promote tumor devel-
opment despite its more widely known role as cell cycle
inhibitor and tumor suppressor [9], (2) the p21 and p53
message levels presented in Figure 3A were in line with
findings in oral squamous cell carcinoma [10], head and
neck cancer [11] and breast cancer [12] indicating that
expression of p21 may be independent of p53, (3)
mCD40-LMP1/iMycEμ-driven BL-like neoplasms in mice
contain elevated levels of p21 mRNA [13] and (4) find-
ings indicate that RelB, which is involved in IL6MYC-
dependent NF-κB activation as shown in Figure 2C, may
be a positive regulator of p21’s oncogenic function [14].
To follow up on the possibility that p21 has oncogenic











Figure 1 MYC and/or IL-6 driven mouse models of human Burkitt
lymphoma (BL) and multiple myeloma (MM). (A) Overview of
transgenic (Tg) mice used in this study. IL6 mice harbor a widely
expressed human interleukin-6 transgene designated H2-Ld-hIL6 [40,41].
MYC mice contain a mouse Myc (c-myc) cDNA transgene that has been
inserted in the immunoglobulin heavy-chain locus with the help of gene
targeting in embryonic stem cells [42]. IL6MYC mice were generated by
intercrossing homozygous-Tg MYC mice and heterozygous-Tg IL6 mice,
followed by selection of double-Tg offspring. All mice were on the genetic
background of BALB/c (C). (B) Photomicrograph of a representative
histologic section of the type of myeloma-like plasma cell tumor that
arises consistently in both IL6 and IL6MYC mice (H&E, original
magnification 40x). Compared to IL6 mice, tumor onset is shorter and
tumor incidence is higher in IL6MYC mice. (C) Representative tissue
section of the main type of tumors observed in MYC mice: Burkitt-like
lymphoblastic B-cell lymphoma that exhibits the typical “starry sky”
morphology due to tingible body macrophages that engulf apoptotic
tumor cells (H&E, original magnification 40x).
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of CDKN1A, we interrogated publicly available gene expres-
sion profiles of human non-Hodgkin lymphomas and MM.
The dataset of Dave et al. [15] (GSE4732) was most helpful
because (1) it permitted us to examine overall survival as a
function of CDKN1A expression, (2) it included only cases
of BL that had been validated using molecular signatures
and (3) survival data was available for a sufficient number of
patients (n = 51). We stratified the patients into 2 groups ac-
cording to high and low CDKN1A expression at diagnosis
(using the median level of p21 as cut-off), generated a
Kaplan-Meier plot (Figure 4A, left) and found that p21High
patients had a significantly worse outcome (p= 0.0126)
compared with their p21Low counterparts. Next, we deter-
mined whether the same held true when patients were first
stratified according to treatment, which was reported for 33
of 51 (65%) cases. Indeed, p21High patients receiving either a
CHOP-like or even more intensive treatment regimen
(INT) fared worse than the p21Low group ((Figure 4A, right).
Unlike BL, survival of p21 expression-stratified DLBCL pa-
tients in the Dave et al. study was not different (Additional
file 1: Figure S1). These results are consistent with an onco-
genic role for p21 in BL and suggest that p21 expression is a
marker of high-risk disease.
Induction of CDKN1A in the course of a drug-induced
stress response in BL cells
The availability of representative tumor cell lines afforded an
opportunity to examine the cancer cell-autonomous proper-
ties of p21 in human BL in greater depth. We selected 5 in-
dependent cell lines, 3 of which are infected with Epstein
Barr virus (EBV) and thus express the virus-encoded onco-
protein LMP1: Daudi, Raji and Jiyoye. Two cell lines, DG75
and Ramos, do not harbor EBV (Figure 4B, bottom). Mouse
Hal2G1 tumor cells, which carry the mCD40-LMP1 and
iMycEμ transgenes [13], were included for comparison. EBV+
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Figure 2 Constitutive activation of NF-κB/Stat3 signaling in malignant B cells and plasma cells of MYC- and/or IL-6-transgenic mice. (A) EMSA
result indicating high levels of NF-κB DNA-binding activity in BL-like lymphomas and MM-like plasma cell tumors that developed in double-transgenic
IL6MYC mice (lanes 2–9) or single-transgenic MYC (lanes 10–14) or IL6 mice (lanes 15–20). Normal B cells (lane 1) were included as control. (B) EMSA result
demonstrating high levels of Stat3DNA-binding activity in the same samples used in panel A. (C) EMSA super-shifts indicating both involvement of p50,
p65, c-Rel and, to a lesser extent, RelB in NF-κB activation and physical association of NF-κB proteins with Stat3 and p300. Red arrowheads denote shifted
bands. In lanes 2–8, NE (10 μg) was incubated with 2 μg of one of the Abs to NF-κB, pStat3 or p300 indicated above the gel image. Antibody to Myc (lane
9) or omission of Ab (lane 1) were used as controls. Red arrowheads denote shifts. (D) EMSA super-shifts suggesting physical association of NF-κB with
pStat3 and p300. Red arrowheads, shifted bands; lanes 2–8, Abs to NF-κB, pStat3 or p300; lanes 1 and 9, controls.
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sage (Figure 4B, center) and p53 DNA-binding activity
(Figure 4C) were consistently low irrespective of EBV/
LMP1 status. Next we measured CDKN1A expression
under conditions of drug-induced stress imposed by
treatment of cells with the cancer-inhibiting agent,
piperlongumine (PL). In agreement with our previous
finding that PL kills human BL and mouse BL-like cells
by virtue of a mechanism that includes inhibition of NF-
κB [13,16], we found that PL kills 3 of 3 BL lines with
similar efficacy (Figure 4D, top). PL-dependent induc-
tion of both CDKN1A (Figure 4D, center) and p53 DNA
binding activity (Figure 4D, bottom) was more robust in
EBV− DG75 cells than in EBV+ Daudi and Raji cells, but
a larger study is warranted to decide whether this istruly associated with EBV/LMP1 status or caused by co-
incidence. Be this as it may, the results described above
implicate the activation of the p53/p21 pathway in the
PL-dependent stress response in BL cells.
FANCD2 is a candidate multiple myeloma (MM) gene
Next, we focused on another candidate gene included in
Figure 3, FANCD2, because the analysis of a clinically
annotated MM dataset for which Affymetrix-based gene
expression results were available suggested that this gene
may be important for myeloma. Figure 5A depicts the
levels of FANCD2 in 351 patients with newly diagnosed
myeloma, according to increasing gene expression. The
mean FANCD2 mRNA level in myeloma cells (351 ±


















































































Figure 3 Gene expression changes in malignant B cells and
plasma cells of MYC- and/or IL-6-transgenic mice. Shown are mean
values and standard deviations of qPCR results obtained in triplicate.
The results of Kruskal-Wallis comparisons of median gene expression
values are indicated to the upper right. (A) Cdkn1a (cyclin-dependent
kinase inhibitor 1A) and Trp53 (transformation related protein 53)
encode the tumor suppressors p21 and p53, respectively. Fancd2,
Fanconi anemia, complementation group D2; Xrcc6, complementation
X-ray repair complementing defective repair in Chinese hamster cells 6.
(B) Aurka, aurora kinase A; Prdm1, PR domain containing 1, with ZNF
domain (aka Blimp-1); Irf1, interferon regulatory factor 1; Egr1, early
growth response 1; Bcl2, B cell leukemia / lymphoma 2. Wild-type
status of Cdkn1a/p21 sequence was confirmed by DNA sequencing
in eight tumors from C.IL6/iMycΔEμ mice (data not shown).
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and 1.8-fold higher than in plasma cells from individuals
with monoclonal gammopathy of undetermined signifi-
cance (MGUS; 195 ± 207, n = 44). Both increases were
highly significant using Mann–Whitney analysis (p < 10−4).
To test the possibility that FANCD2 expression is of prog-
nostic significance in myeloma, we used the median
FANCD2 level in myeloma cells (291 array units) as a cut-
off to determine event-free survival (EFS) and overall sur-
vival (OS) separately in FANCD2Low patients (n = 175)
versus FANCD2High patients (n = 176). Both EFS (p =
0.004) and OS (p = 0.028) were significantly shorter in the
FANCD2High cohort using log-rank analysis (Figure 5B).These findings suggested that up-regulation of FANCD2
leads to increased myeloma aggressiveness.
FANCD2 is associated with high-risk myeloma
Keeping in mind that the prognosis of myeloma depends
in large measure on tumor genetics [17] and that risk
stratification models of myeloma rely on genetic features,
such as changes in gene expression according to the 70-
gene model [18], to assign newly diagnosed cases to
standard-risk groups (median OS >10 years) and high-risk
groups (2–3 years) [19], we analyzed whether FANCD2High
status might be associated with high-risk disease as defined
by the 70-gene signature [18]. Forty-six of 351 myeloma
patients (13%) carried this signature (Figure 5C), with most
of them falling into four subgroups of myeloma: prolifera-
tion (PR, n = 20), MAF/MAFB (MF, n = 12), MMSET (MS,
n = 9) and hyper-diploid (HY, n = 4). In all four subgroups,
mean FANCD2 levels were elevated in high-risk relative to
standard-risk disease, but statistical significance was only
reached in one subgroup, PR (p = 0.0043, Mann–Whitney
test (Figure 5D, left). When all 46 high-risk cases were
pooled and the mean FANCD2 expression level of
that pool was compared to all 305 standard-risk
cases, the up-regulation of FANCD2 in high-risk mye-
loma was highly significant (p = 0.004; Figure 5D,
right). This result suggested that FANCD2 is a bona
fide high-risk myeloma gene as defined by the
70-gene model.
Discussion
The main finding of this study is the implication of
FANCD2 and CDKN1A in high-risk MM and BL, respect-
ively. CDKN1A was first identified as an inhibitor of cell
cycle progression and tumor development that is up regu-
lated by wild-type p53 [20,21]. Nowadays CDKN1A is
more broadly considered as a regulator of fundamental
cell-fate decisions, such as proliferation, differentiation
and senescence [22]. With respect to oncogenesis, the
tumor suppressor function of CDKN1A is well established,
yet there is also growing evidence for oncogenic properties
of CDKN1A-encoded p21. For instance, p21 is overex-
pressed in mouse fibroblasts undergoing transformation
induced by ionizing radiation [23]. The underlying mech-
anism is not known but likely includes protection from
apoptosis, which is emerging as key for p21’s oncogenic
functions [24]. In line with that, cytoplasmic p21, the ac-
cumulation of which is stimulated by AKT- or IKKβ-
dependent pathways, suppresses programmed cell death
[25]. Furthermore, NF-κB-dependent up-regulation of p21
inhibits apoptosis in cells damaged by doxorubicin [26] or
UV irradiation [27]. Importantly, tumor development
studies in laboratory mice have demonstrated that dele-
tion of Cdkn1a inhibits lymphoma in Trp53-deficient












































































































































Figure 4 CDKN1A expression prognosticates poor outcome in human BL. (A) Kaplan-Meier curves indicating decreased survival of BL patients
expressing high levels of p21 message (Mantel-Cox log-rank analysis). Data are from Dave et al. (GSE4732, probe 202284) [15]. The left panel depicts survival
of 51 patients evenly split according to p21 expression into a p21Low group and a p21High group. The former demonstrated better outcome (p = 0.0126).
The right panel shows survival of 33 patients treated with either a CHOP-like regimen or an intensive (INT) drug regimen supplemented in some cases with
autologous hematopoietic stem cell transplantation. p21Low patients demonstrated better outcomes than p21High patients in both treatment arms. (B)
CDKN1A and TP53 expression in 5 human BL cell lines and 1 mouse BL-like cell line, Hal1, derived from a LMP1-transgenic lymphoma. Daudi, Raji and Jiyoye
are EBV+ and thus express virus-encoded LMP1. DG75 and Ramos are EBV-. Because LMP1 activates NF-κB in malignant B cells [43], it is possible that p21
expression in LMP1+ cells is driven, in part, by LMP1. (C) EMSA indicating p53 DNA-binding activity in BL and normal B cells. (D) Piperlongumin (PL)-induced
activation of the p53-p21 stress response in BL cells. Shown at the top is the growth inhibition of cells upon treatment with 10 μM or 15 μM PL for 24 hrs
(MTS assay). Mean values and error bars, which represent the standard deviation from triplicate experiments, are plotted. The center panel shows the
corresponding p21 message levels (qPCR). Differences in both panels were not significant (Mann–Whitney, p = 0.1). Presented at the bottom are the
corresponding EMSA results at 24 hrs, indicating that the drug dose-dependent induction of p53 DNA-binding activity was more vigorous at 10 μM PL
in EBV− DG75 cells compared to EBV+ Daudi and Raji cells.
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Figure 5 FANCD2 expression predicts poor survival in a subset of
patients with newly diagnosed multiple myeloma. (A) FANCD2 mRNA
levels (gene probe ID 242560) in normal bone marrow (BM) plasma cells
(NPC, green), “premalignant” BM plasma cells from individuals with
monoclonal gammopathy of undetermined significance (MGUS, purple)
or malignant plasma cells from patients with multiple myeloma (MM,
black). (B) Reduced event-free survival (EFS) and overall survival (OS) in
myeloma patients with elevated FANCD2 levels (log-rank analysis). Of 351
patients, 175 and 176 patients were arbitrarily categorized as “Low
FANCD2” and “High FANCD2,” respectively, using the median FANCD2
level in this cohort as cut-off. EFS and OS data were available from 129
(37%) and 85 (24%) patients, respectively. (C) Proportion of myelomas
(n = 351) that fell into 8 different subgroups of the disease based on
cytogenetic features (e.g., ploidy and chromosomal translocations) and
molecular genetic features (e.g., gene expression signatures). From top to
bottom, the following subgroups are distinguished: MF, MAF/MAFB; CD1,
CCND1/CCND3 group 1; PR, proliferation; LB, low bone disease; CD2,
CCND1/CCND3 group 2; MS, MMSET; HY, hyperdiploid; MY, myeloid [39].
The distribution of standard-risk (blue) and high-risk cases (red) according
to the 70-gene signature [18] is also indicated. (D) Shown to the left is
elevation of FANCD2 message in high-risk myeloma (red) vs. standard-risk
myeloma (blue) in 4 of 8 subgroups of the disease included in panel C.
Mean values (microarray units) and standard error of the mean (SEM) are
plotted. Mann–Whitney tests were used for statistical analyses (n. s., not
significant). Shown to the right is the increase in FANCD2 mRNA in
high-risk disease (red; 13%) vs. standard-risk disease (blue; 87%) in 351
myeloma patients. Mean values and SEM are plotted. Median FANCD2
levels in high-risk and standard-risk disease were 473 and 269, respectively.
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of a tumor suppressor gene. In further agreement with
p21’s survival-enhancing activity, lymphomas arising in
Cdkn1a-deficient mice demonstrate a high rate of apop-
tosis [31]. In human cancers, overexpression of CDKN1A
is frequently seen in carcinoma (prostate, cervix, breast,
ovary, skin), brain tumor (glioma) and hematological ma-
lignancy [25]. With regard to the latter, strong experimen-
tal evidence indicates that p21’s pro-survival function
plays an important role in the natural history of human
leukemia [32]. These findings support the result of this
study suggesting that p21 promotes BL by functioning as
an oncogene in the mature B-cell lineage.
The observed overexpression of Fancd2 and Xrcc6 in
myeloma-like plasma cell tumors from IL6MYC mice
established an interesting parallel to human MM, in which
the Fanconi anemia/breast cancer (FA/BRCA) DNA dam-
age repair pathway has been identified as an important ef-
fector mechanism of myeloma cell responses to replicative
stress induced by DNA alkylating agents, such as the widely
used myeloma drug melphalan [33]. FA/BRCA has also
been implicated in the acquisition of drug including borte-
zomib resistance by myeloma cells [34]. FANCD2 is a key
player in the FA/BRCA pathway and XRCC6 is a facilitator
of DNA double-strand break repair. Both repair proteins
are subject to regulation by NF-κB (e.g., p50/RelB dimers)
[33,35,36] and both intersect functionally with p21. The lat-
ter is illustrated by reports that p21 can activate FA-BRCA-
dependent [37] and XRCC6-dependent [38] DNA repair,
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In this study, we provided clinical evidence for a role of
FANCD2 in myeloma. Unlike XRCC6 expression, which
was not associated with survival in the Total Therapy 2
(TT2) myeloma dataset used here (n = 351), the message
levels of FANCD2 were significantly correlated with event-
free and overall survival of patients with myeloma. More-
over, overexpression of FANCD2 appeared to be a feature
of high-risk myeloma, a subset of the disease for which new
therapeutic approaches are urgently needed. Patients with
high-risk myeloma have extremely poor outcomes; as such,
they define an unmet medical need. The median overall
survival for patients with standard-risk myeloma is >10
years years, yet that for patients with high-risk disease is 2–
3 years, despite the application of aggressive, risk-adapted
therapies including tandem autologous stem-cell trans-
plantation (ASCT) and new myeloma drugs [19]. The re-
sults presented here support the view that FANCD2 may
be a bone fide high-risk myeloma gene that is worthy for
consideration as molecular target for new, targeted therap-
ies of patients with MM.
Conclusion
Starting with the observation that IL-6 and/or MYC-
driven B cell and plasma cell tumors in BALB/c mice ex-
hibit constitutive NF-κB/STAT3 activity that leads to
up-regulation of NF-κB target genes, we found that two
genes of this sort, CDKN1A and FANCD2, are important
for human BL and human MM, respectively. It is pos-
sible that these genes drive neoplastic development in
the mature B-cell lineage, but this has not been demon-
strated here. Additional functional and mechanistic
studies are warranted before it can be decided whether
CDKN1A and FANCD2 provide viable molecular targets
for new therapeutic approaches to BL and MM. MYC-
driven BL-like tumors and IL6MYC-driven MM-like tu-
mors in laboratory mice may lend themselves as experi-
mental model systems to that end.
Methods
Transgenic mice, human BL cell lines, and normal B-
lymphocytes
The generation and tumor phenotypes of single-transgenic
MYC [1] or IL6 [2] mice and double-transgenic IL6MYC
mice [3,4] have been previously reported. All transgenes
were on the genetic background of BALB/c (C). Breeding,
maintenance and handling of mice was conducted accord-
ing to IACUC guidelines and approved under University of
Iowa ACURF study protocol 1301010. Human Burkitt
lymphoma (BL) cell lines, purchased from ATCC (Manas-
sas, VA), were maintained in RPMI 1640 supplemented
with 10% heat-inactivated fetal bovine serum, in a humidi-
fied 5% CO2 incubator at 37°C. Human B cells were isolated
from peripheral blood of healthy individuals as previouslydescribed [16]. Normal B220+ B cells were fractionated from
the spleen of inbred C mice, using MACS® CD45R magnetic
beads columns from Miltenyi Biotec (Auburn, CA).
Quantitative reverse-transcription PCR (qPCR)
Reverse transcription, performed on 1 μg of TRIzol
(Sigma-Aldrich, St. Louis, MO)-extracted total RNA,
was followed by cDNA synthesis using the AMV reverse
transcriptase kit (Roche, Indianapolis, IN). qPCR was
performed with the help of TaqMan Universal PCR
Master Mix (Applied Biosystems, Carlsbad, CA), using
primers and 6-carboxyfluorescein (6-FAM) / Black Hole
(BHQ)-labelled probes to specific target genes (IDT,
Coralville, IA). Sequences of probes are available upon
request. The Applied Biosystems 7900 HT device was
used for amplification and detection of PCR product.
ABI SDS v 2.3 software (Applied Biosystems, Carlsbad,
CA) was employed for analyzing results. The Ct value
for each gene was normalized to the internal reference
control, HPRT1 for human genes or Hprt for mouse
genes, and represented as fold gene expression change
relative to gene expression in normal human or mouse
B cells or, in case of drug studies, to vehicle-treated
cells.
Cell proliferation
Proliferation was determined using the Cell Titer 96®
MTS/PMS assay (Promega, Madison, WI). Briefly, 1 x
105 cells in 100 μl growth media were plated into 96-
well plates (Costar, Cambridge, MA). After 20 hours, 20
μl of MTS/PMS solution was added per well. Four hours
later, the absorbance at 490 nm was measured using a
Multiskan Spectrum plate reader (Thermo Scientific,
Hudson, NH).
Preparation of nuclear and cytosolic extracts
Cells (1 × 107) were lysed with 400 μl of buffer A (10 mM
KCl, 0.2 mM EDTA, 1.5 mM MgCl2, 0.5 mM DTT, and
0.2 mM PMSF) at 4°C for 10 minutes. Lysate was centri-
fuged for 5 minutes at 14,000 g and supernatants were col-
lected as cytosolic extracts. Pellet was re-suspended in 100
μl ice-cold buffer C (20 mM HEPES [pH 7.9], 420 mM
NaCl, 1.5 mM MgCl2, 20% [v/v] glycerol, 0.2 mM EDTA,
0.5 mM DTT, and 0.2 mM PMSF), incubated at 4°C for
20 minutes and centrifuged for 6 minutes at 14,000 g.
Supernatant was collected as nuclear extract (NE). Protein
concentration of NE was determined using a BCA kit
(Bio-Rad, Richmond, CA).
Electrophoretic mobility shift assays (EMSA)
EMSA was carried out in 25 μl of binding buffer (10 mM
Tris [pH 7.5], 100 mM NaCl, 1 mM DTT, 1 mM EDTA,
4% [w/v] glycerol, 0.1 mg/ml sonicated salmon sperm
DNA), using 10 μg of NE. Oligonucleotides containing
Han et al. Experimental Hematology & Oncology  (2015) 4:9 Page 9 of 10consensus NF-κB (Promega, Madison, WI), MYC/MAX
or p53 DNA recognition and binding sites (Santa Cruz
Biotechnology, Santa Cruz, CA) were end-labeled to a
specific activity of 105 CPM, using γ-[32P]-ATP and T4-
polynucleotide kinase followed by purification on a Nick
column (GE Healthcare, Piscataway, NJ). Reaction mix-
tures were incubated at room temperature for 20 minutes
and resolved on 6% non-denaturing polyacrylamide gels.
Gels were dried and subjected to autoradiography. For
super-shift assays, 2 μg antibody was added (20 min, am-
bient temperature) after the reaction with radiolabeled
oligonucleotide had been completed. Antibodies to p50
(sc-114X), p65 (sc-109X), c-Rel (sc-70X), p52 (sc-298X),
RelB (sc-48366X) or Myc (sc-764X) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA).
Microarray-based gene expression profiling (GEP)
GEP using the Affymetrix U133Plus 2.0 microarray (Santa
Clara, CA) were performed as previously described [39].
Microarray data and outcome data on the 351 patients in-
cluded in this study are available in the NIH Gene Expres-
sion Omnibus (GEO) under accession number GSE2658.
Microarray data on the 44 individuals with MGUS and 22
samples of normal plasma cells (NPC) included here are
available at GSE5900. Plasma-cell isolation, total RNA ex-
traction, cRNA synthesis, and hybridization to microarrays
were performed as described previously [18]. Statistical ana-
lysis of microarray data took advantage of the GCOS1.1
software (Affymetrix, Santa Clara, CA) and involved log-
rank tests for univariate association with disease-related
survival.
Additional file
Additional file 1: Figure S1. Kaplan-Meier curves showing overall
survival of DLBCL patients according to high or low expression of CDKN1A
(202284_s_at). Data were mined from Dave et al. (GSE4732) [15]. Vertical hash
marks represent a live patient at the indicated follow-up time. Mantel-Cox
log-rank analysis was used to compare patient groups (not significant). Survival
was recorded for 51 patients according to high and low p21 expression at
diagnosis (left). Survival was also plotted for patients treated with either CHOP
or a more intensive (INT) regimen (right).
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